Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions

被引：9

作者：

Iacovelli, Roberto ^{[1
,2
]}

Ciccarese, Chiara ^{[2
]}

Schinzari, Giovanni ^{[1
]}

Maiorano, Brigida Anna ^{[1
]}

Rossi, Ernesto ^{[1
]}

Pierconti, Francesco ^{[2
,3
]}

Bassi, Pier Francesco ^{[2
,4
]}

Bria, Emilio ^{[1
,2
]}

Tortora, Giampaolo ^{[1
,2
]}

机构：

[1] Fdn Policlin Univ A Gemelli IRCCS, Oncol Med, Rome, Italy

[2] Univ Cattolica Sacro Cuore, Rome, Italy

[3] Fdn Policlin Univ A Gemelli IRCCS, UOC Anat Patol, Rome, Italy

[4] Fdn Policlin Univ A Gemelli IRCCS, Dept Urol, Rome, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2019年 / 139卷

关键词：

De-novo metastatic castration sensitive prostate cancer; De-novo mCSPC; Local radiotherapy; Abiraterone; Low-risk; Prognostic;

D O I：

10.1016/j.critrevonc.2019.05.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

De-novo metastatic castration sensitive prostate cancer (mCSPC) is a subgroup of prostate cancer associated with poor prognosis. Recently, the treatment of mCSPC has been enriched by new life-prolonging options, including the combination of docetaxel or abiraterone acetate with androgen deprivation therapy (ADT). Of note, the advantage of chemohormonal therapy was more relevant in the subgroup of high-volume disease compared to low-volume, while the survival prolongation of abiraterone was observed only in high-risk patients. Choosing the most appropriate therapy is one of the most debated issues. This review describes the latest news on de-novo mCSPC to better outline patients' management. At the ESMO 2018 Congress two novel studies focused on this setting have been presented, trying to define the role of radiotherapy to the primary tumour and the efficacy of abiraterone acetate in the subset of low-risk patients. We have analysed these results in light of the evidence already available.

引用

页码：83 / 86

页数：4

共 20 条

[1] The Molecular Taxonomy of Primary Prostate Cancer [J].

Abeshouse, Adam ;

Ahn, Jaeil ;

Akbani, Rehan ;

Ally, Adrian ;

Amin, Samirkumar ;

Andry, Christopher D. ;

Annala, Matti ;

Aprikian, Armen ;

Armenia, Joshua ;

Arora, Arshi ;

Auman, J. Todd ;

Balasundaram, Miruna ;

Balu, Saianand ;

Barbieri, Christopher E. ;

Bauer, Thomas ;

Benz, Christopher C. ;

Bergeron, Alain ;

Beroukhim, Rameen ;

Berrios, Mario ;

Bivol, Adrian ;

Bodenheimer, Tom ;

Boice, Lori ;

Bootwalla, Moiz S. ;

dos Reis, Rodolfo Borges ;

Boutros, Paul C. ;

Bowen, Jay ;

Bowlby, Reanne ;

Boyd, Jeffrey ;

Bradley, Robert K. ;

Breggia, Anne ;

Brimo, Fadi ;

Bristow, Christopher A. ;

Brooks, Denise ;

Broom, Bradley M. ;

Bryce, Alan H. ;

Bubley, Glenn ;

Burks, Eric ;

Butterfield, Yaron S. N. ;

Button, Michael ;

Canes, David ;

Carlotti, Carlos G. ;

Carlsen, Rebecca ;

Carmel, Michel ;

Carroll, Peter R. ;

Carter, Scott L. ;

Cartun, Richard ;

Carver, Brett S. ;

Chan, June M. ;

Chang, Matthew T. ;

Chen, Yu .

CELL, 2015, 163 (04) :1011-1025

[2]

[Anonymous], ANN ONCOL S8

[3]

Boevé LMS, 2019, EUR UROL, V75, P410, DOI 10.1016/j.eururo.2018.09.008

[4] Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study [J].

Culp, Stephen H. ;

Schellhammer, Paul F. ;

Williams, Michael B. .

EUROPEAN UROLOGY, 2014, 65 (06) :1058-1066

[5]

FIZAZI K, 2017, J CLIN ONCOL S, V35, pNIL10

[6] Abiraterone acetate plus prednisone in patients with newly Croatia& diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial [J].

Fizazi, Karim ;

NamPhuong Tran ;

Fein, Luis ;

Matsubara, Nobuaki ;

Rodriguez-Antolin, Alfredo ;

Alekseev, Boris Y. ;

Ozguroglu, Mustafa ;

Ye, Dingwei ;

Feyerabend, Susan ;

Protheroe, Andrew ;

Sulur, Giri ;

Luna, Yesenia ;

Li, Susan ;

Mundle, Suneel ;

Chi, Kim N. .

LANCET ONCOLOGY, 2019, 20 (05) :686-700

[7] Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer [J].

Fizazi, Karim ;

NamPhuong Tran ;

Fein, Luis ;

Matsubara, Nobuaki ;

Rodriguez-Antolin, Alfredo ;

Alekseev, Boris Y. ;

Ozguroglu, Mustafa ;

Ye, Dingwei ;

Feyerabend, Susan ;

Protheroe, Andrew ;

De Porre, Peter ;

Kheoh, Thian ;

Park, Youn C. ;

Todd, Mary B. ;

Chi, Kim N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (04) :352-360

[8] Identifying Optimal Candidates for Local Treatment of the Primary Tumor Among Patients Diagnosed with Metastatic Prostate Cancer: A SEER-based Study [J].

Fossati, Nicola ;

Quoc-Dien Trinh ;

Sammon, Jesse ;

Sood, Akshay ;

Larcher, Alessandro ;

Sun, Maxine ;

Karakiewicz, Pierre ;

Guazzoni, Giorgio ;

Montorsi, Francesco ;

Briganti, Alberto ;

Menon, Mani ;

Abdollah, Firas .

EUROPEAN UROLOGY, 2015, 67 (01) :3-6

[9] Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial [J].

Gravis, Gwenaelle ;

Boher, Jean-Marie ;

Joly, Florence ;

Soulie, Michel ;

Albiges, Laurence ;

Priou, Franck ;

Latorzeff, Igor ;

Delva, Remy ;

Krakowski, Ivan ;

Laguerre, Brigitte ;

Rolland, Frederic ;

Theodore, Christine ;

Deplanque, Gael ;

Ferrero, Jean-Marc ;

Culine, Stephane ;

Mourey, Loic ;

Beuzeboc, Philippe ;

Habibian, Muriel ;

Oudard, Stephane ;

Fizazi, Karim .

EUROPEAN UROLOGY, 2016, 70 (02) :256-262

[10] Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer [J].

Iacovelli, Roberto ;

Ciccarese, Chiara ;

Mosillo, Claudia ;

Bimbatti, Davide ;

Fantinel, Emanuela ;

Stefani, Lisa ;

Simbolo, Michele ;

Romano, Mario ;

Mazzarotto, Renzo ;

Brunelli, Matteo ;

Bria, Emilio ;

Scarpa, Aldo ;

Lawlor, Rita T. ;

Artibani, Walter ;

Tortora, Giampaolo .

TARGETED ONCOLOGY, 2018, 13 (05) :649-655

← 1 2 →